Magdalena Lang

Human Potential & Healthtech

The session’s core message was that healthtech progress is being driven by the combination of human imagination, clinical pain points, and increasingly capable technologies that can act closer to biology itself. Moderator KIVA Vallely framed the discussion around breakthroughs that begin when someone identifies an unsolved healthcare problem, then introduced speakers working at different points of the healthtech stack: neuroelectronics at the brain interface, AI for life sciences workflows, and automated laboratories for bioengineering. In the available transcript, the conversation moved quickly from broad human potential into concrete examples of how technology is changing what can be measured, interpreted, and acted upon in healthcare. Carolina Aguilar described the nervous system as a vast, still poorly understood frontier, noting that one in three people have a neurological related disorder and contrasting the mapped brain of a zebrafish with the scale of the human brain. She argued that future implants, biofeedback, and training could help the nervous system self-repair, beginning with symptom relief and eventually broader rewiring possibilities. INBRAIN’s initial focus on Parkinson’s disease was presented as a deliberate choice because existing implant therapies, reimbursement coverage, known biology, and clinical pathways make it a practical first indication, especially for patients refractory to drugs. Martin Copes then shifted the lens from direct patient-facing neurotechnology to the research and development workflows behind medicines. He said pharma and biotech teams now face an abundance of data, models, and biological knowledge, but need ways to connect context across preclinical research and clinical work. His emphasis was that large language models and AI can help recreate a modern “polymath” capability by pulling together fragmented scientific information, while humans continue to apply intuition, critical judgment, and strategic exploration. Magdalena Lang extended that point into drug development and bioengineering, arguing that AI has been heavily applied in discovery, while bottlenecks are moving downstream into scalable, reproducible process development and manufacturing readiness. She described autonomous or semi-autonomous labs needing AI and data layers that ingest sensor and assay data into continuous feedback loops. The available segment closed with Carolina explaining how AI is embedded in brain implant software, including multimodal interpretation of neural signals, symptoms, drugs, and patient context, with a goal of enabling faster device programming rather than making patients wait months for clinical adjustments.